Company intelligence / Profile preview

GOL

Zurich, Zurich, Switzerland

Ownership: Private
Employees: ~25
Development stage: Other

Overview

GOL Pharma is a biotechnology company focused on developing therapies that target the fundamental biological processes of aging. By leveraging a proprietary platform centered on longevity genetics, the company identifies and modulates key pathways such as Sirtuin 1 and AMPK to treat age-related conditions. Their research aims to extend healthy lifespan and address metabolic and neurodegenerative disorders through innovative small molecule and peptide-based interventions. GOL Pharma is currently in the pre-clinical stage, advancing a pipeline of candidates designed to promote cellular health and resilience.

Therapeutic areas: NeurologyMetabolic DisordersOther
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on GOL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GOL.

Explore the full profile